Posted by Michael Wonder on 22 Mar 2018
FDA approves Genentech’s Lucentis (ranibizumab injection) 0.3 mg pre-filled syringe for diabetic macular oedema and diabetic retinopathy
21 March 2018 - Pre-filled syringe options are now FDA-approved for all Lucentis indications.
Genentech today announced that the U.S. FDA approved the Lucentis (ranibizumab injection) 0.3 mg pre-filled syringe (PFS) as a new method of administering the medicine to treat all forms of diabetic retinopathy.
In April 2017, Lucentis 0.3 mg became, and remains, the first and only FDA-approved medicine to treat all forms of diabetic retinopathy in people with or without diabetic macular edema (DME), a complication of the eye disease that causes swelling in the back of the eye. The Lucentis 0.3 mg PFS is now the first syringe pre-filled with an anti-vascular endothelial growth factor agent FDA-approved to treat both diabetic retinopathy and DME.
